Article Text

other Versions

Clinical science
Is ranibizumab effective in stopping the loss of vision for choroidal neovascularisation in pathologic myopia? A long-term follow-up study
  1. Maria Vadalà1,
  2. Alfredo Pece2,
  3. Stefano Cipolla1,
  4. Carla Monteleone1,
  5. Giuseppe Fasolino3,
  6. Alessandra Casuccio1,
  7. Salvatore Cillino1
  1. 1Dipartimento di Biomedicina Sperimentale e Neuroscienze Cliniche, Sezione di Oftalmologia, Università di Palermo, Italy
  2. 2Unità operativa di Oftalmologia, Ospedale di Melegnano, via Pandina, Melegnano, Milano, Italy
  3. 3Unità operativa di Oculistica, Casa di Cura Villa Tiberia, Roma, Italy
  1. Correspondence to Dr Maria Vadalà, Dipartimento di Neuroscienze Cliniche, Sezione di Oftalmologia, Università di Palermo, via L. Giuffrè 13, 90127 Palermo, Italy; maria.vadala{at}


Aim To assess the efficacy and safety of ranibizumab in the treatment of choroidal neovascularisation (CNV) caused by pathologic myopia (PM).

Design Prospective, multicentre, interventional case series.

Methods 40 eyes of 39 consecutive patients with PM and CNV were treated with ‘on demand’ intravitreal injection of ranibizumab 0.5 mg. Final best corrected visual acuity (BCVA) and its change from baseline were the main outcome measures. Changes in optical coherence tomography (OCT) central retinal thickness (CRT) were a secondary outcome.

Results Mean age was 53±13 years and mean refractive error –13.5±6.5 D. Median follow-up was 13.3±2 (range 12–18) months. Fifteen eyes (37.5%) had previously been treated with photodynamic therapy (PDT). The mean baseline logarithm of the minimum angle of resolution (logMAR) BCVA (Early Treatment Diabetic Retinopathy Study (ETDRS) vision chart) was 0.68±0.34 (Snellen equivalent 20/131) and 21±16 letters. The final mean logMAR BCVA was 0.27±0.2 (p = 0.008) (20/42) and 40.5±14 letters (p = 0.01). Mean final VA improved in 82.5% of patients, in 60% by 3 or more lines (median number of lines gained 2.9). Even six out of seven cases of low vision (≤1.1 logMAR) at the final examination has improved vision. Mean OCT CRT reduced from 218±70 to 175±46 μm (p 0.02). Age and previous PDT did not influence the results (p>0.05). The mean number of injection was 2.8±1.2 (range 1–6). No ocular or systemic side effects were observed.

Conclusion Ranibizumab was an effective treatment for stabilising and improving vision with a low number of injections in 92.5% of patients with myopic CNV in a long-term follow-up.

  • Pathological myopia
  • choroidal neovascularisation
  • ranibizumab
  • intraocular injection
  • anti-VEGF drug
  • drugs

Statistics from


  • Competing interests None to declare.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.